Results 11 to 20 of about 64,832 (295)

Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.

open access: greenJournal of Advanced Pharmaceutical Technology & Research, 2012
Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients. Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea ...
Prasan R Bhandari
doaj   +2 more sources

Psychological Interventions in Chemotherapy-Induced Nausea and Vomiting in Women with Breast Cancer: A Systematic Review [PDF]

open access: yesIranian Journal of Medical Sciences, 2022
Background: Nausea and vomiting are considered the most common side effects of chemotherapy, and they can affect different dimensions of the lives of women with breast cancer. Thus, the management of these complications is of great significance.
Elahe Samami   +3 more
doaj   +1 more source

Effect of Foot Massage on Patients with Chemotherapy Induced Nausea and Vomiting: A Randomized Clinical Trial [PDF]

open access: yesJournal of Caring Sciences, 2020
Introduction: Cancer is a global problem and it is a leading cause of death worldwide. Nausea, vomiting and retching are one of the common side effects that are seen among the majority of the patients undergoing chemotherapy.
Cluny Asha   +2 more
doaj   +1 more source

Comparative Study of an Ondansetron and a Ramosetron an Aprepitant in the Control of Nausea and Vomiting in Gynecologinc Cancer Patient with Chemotherapy [PDF]

open access: yesKosin Medical Journal, 2013
ResultsThe efficacy of controlling nausea with an ondansetron regimen and a ramosetron regimen and an aprepitant regimen was 85.29%, 78.26%, 80% in acute periods (P-value = 0.037) and 88.23%, 98.26%, 87.5% in delayed periods (P-value = 0.000 ...
HANGGOO Yun, Heung Yeol Kim, Eun ae Jeh
doaj   +1 more source

Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy

open access: yesОпухоли женской репродуктивной системы, 2023
Chemotherapy-induced nausea and vomiting is a common problem during cancer treatment, especially in breast cancer patients with anthracycline/cyclophosphamide (ас) chemotherapy.
A. G. Kedrova, A. I. Berishvili
doaj   +1 more source

Acupuncture for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients: A systematic review and meta‐analysis

open access: yesCancer Medicine, 2023
To assess the effectiveness and safety of acupuncture for the prevention of chemotherapy‐induced nausea and vomiting (CINV), with a specific intention on exploring sources of between‐study variation in treatment effects.
Yuqian Yan   +5 more
semanticscholar   +1 more source

Knowledge, practice and perceived barriers towards chemotherapy induced nausea and vomiting in prophylaxis guideline adherence among nurses in oncology units at selected hospitals, in Addis Ababa, Ethiopia, a cross-sectional study

open access: yesBMC Nursing, 2022
Background Chemotherapy-induced emesis can be prevented by the use of recommended guidelines for antiemetic regimens but a research study indicates that in Ethiopia the use of standard antiemetic drug guidelines is very limited.
Deneke Gebre   +3 more
doaj   +1 more source

Penerapan Akupresur dalam Mengurangi Mual Muntah pada Pasien Kanker dengan Kemoterapi [PDF]

open access: yes, 2022
This study aims to analyze the use of acupressure in reducing chemotherapy-induced nausea and vomiting. The method used is a systematic review through the Proquest database, ScienceDirect and Scopus. The results showed that of the eight articles reviewed,
Allenidekania, Allenidekania   +2 more
core   +3 more sources

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy